Exact Mass: 679.3203744
Exact Mass Matches: 679.3203744
Found 82 metabolites which its exact mass value is equals to given mass value 679.3203744,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Thymin
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D007155 - Immunologic Factors
Arg Arg Trp Tyr
Arg Arg Tyr Trp
Arg Trp Arg Tyr
Arg Trp Tyr Arg
Arg Tyr Arg Trp
Arg Tyr Trp Arg
Trp Arg Arg Tyr
Trp Arg Tyr Arg
Trp Tyr Arg Arg
Tyr Arg Arg Trp
Tyr Arg Trp Arg
Tyr Trp Arg Arg
Thymopentin
L - Antineoplastic and immunomodulating agents > L03 - Immunostimulants > L03A - Immunostimulants D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D007155 - Immunologic Factors Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs)[1][2]. Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs)[1][2]. Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs)[1][2].
Thymopentine
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones C308 - Immunotherapeutic Agent > C2139 - Immunostimulant D007155 - Immunologic Factors
1-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
C34H48F3N5O6 (679.3556503999998)
1-[[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
C34H48F3N5O6 (679.3556503999998)
5-methoxycarbonylpentyl 4,6-dideoxy-4-formamido-2-O-methyl-alpha-D-mannopyranosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannopyranosyl-(1->3)-4,6-dideoxy-4-formamido-alpha-D-mannopyranoside
Fibrinogen-Binding Peptide (TFA)
Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin[1].
n-(1-oxo-1-{[(8e,10e,16z)-3,15,27-trihydroxy-5-methoxy-14,16-dimethyl-22-thia-2,24-diazatricyclo[18.6.1.0²¹,²⁵]heptacosa-1(27),2,6,8,10,16,20,23,25-nonaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid
(1s,3r,5r,7s,8e,14e,16e,18e,20e,22s,24r,25s,26r)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
22-[(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy]-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
(1r,2s,3s,7s,10r,13r,14s,15r,17r,18r,19r)-8,15,17,18-tetrahydroxy-7-(2-methanesulfinylethyl)-3,19-dimethoxy-2,14,18-trimethyl-10-(2-methylpropyl)-13-propyl-6,12,21-trioxa-9-azabicyclo[15.3.1]henicos-8-ene-5,11-dione
C32H57NO12S (679.3601282000001)
(1r,3s,5r,7r,8e,12r,13s,14e,16e,18e,20e,22r,24s,25r,26s)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
2-[2-(6-{[(3r,4ar,8s,11r,14s)-3,9,12-trihydroxy-14-methyl-11-(2-methylpropyl)-5,15-dioxo-1h,2h,3h,4h,4ah,7h,8h,11h,14h-pyridazino[3,2-c]1-oxa-4,7,10-triazacyclotridecan-8-yl]-c-hydroxycarbonimidoyl}-5,6-dihydro-4h-pyridazin-1-yl)-2-oxoethyl]heptanoic acid
C31H49N7O10 (679.3540734000001)
n-[(2r,3s,4s,5s,6r)-6-{[(1s,5r,7e,9r,10r,11s,12s,13s)-5-[(1e,3e)-6-[(1r,2s)-2-chlorocyclopropyl]hexa-1,3-dien-5-yn-1-yl]-1-hydroxy-9-methoxy-7,10,12-trimethyl-3-oxo-4,15-dioxabicyclo[9.3.1]pentadec-7-en-13-yl]oxy}-4-hydroxy-5-methoxy-2,4-dimethyloxan-3-yl]carboximidic acid
2-[2-(6-{[(4ar,8s,11r,14s)-9,12-dihydroxy-14-methyl-11-(2-methylpropyl)-5,15-dioxo-1h,2h,3h,4h,4ah,7h,8h,11h,14h-pyridazino[3,2-c]1-oxa-4,7,10-triazacyclotridecan-8-yl]-c-hydroxycarbonimidoyl}-5,6-dihydro-4h-pyridazin-1-yl)-2-oxoethyl]-6-hydroxyheptanoic acid
C31H49N7O10 (679.3540734000001)